Verschlimmbesserung: Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37823794.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2331 and PMC identifier 10722133.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Standard-risk WNT medulloblastoma patients have an excellent prognosis (>90% progression-free survival) using the combination of standard dose craniospinal radiotherapy (CSI) (23.4 Gy) followed by platinum and alkylator based chemotherapy. A recent pilot study that attempted to completely omit radiotherapy was terminated early as all patients (n = 3) relapsed rapidly (on treatment or within 6 months of completing treatment). The study highlights that therapy is the most important prognostic factor, with CSI still required to cure even the most favorable subgroup of medulloblastoma patients. See related article by Cohen et al., p. 5031.
Medical subject headings
- Medulloblastoma
- Cerebellar Neoplasms
- Craniospinal Irradiation